Singh-Grewal D, Kemp A, Wong M
Department of Allergy, Immunology and Infectious Diseases, The Children's Hospital at Westmead, Locked Bag 4001, Westmead, Sydney, New South Wales, Australia 2145.
Arch Dis Child. 2006 Aug;91(8):651-4. doi: 10.1136/adc.2005.078733. Epub 2006 Apr 25.
To document the incidence of immediate and delayed adverse events (AE) following intravenous immunoglobulin (IVIG) infusion in children.
Immediate and delayed adverse events were prospectively recorded for 345 infusions in 58 children receiving IVIG for immunodeficiency (n = 33) or immunomodulation (n = 25). For each infusion adverse events were documented during the infusion and by follow up interview 4-7 days later.
Immediate adverse events occurred in 10.3% and delayed adverse events in 41.4% of children treated during the study period. Three and a half per cent of the infusions were associated with immediate AE and 20.9% with delayed adverse events. Headache was the most common delayed AE, occurring in 24.1% of patients and 12.8% of infusions.
Delayed adverse events to IVIG infusions are common in children. They occur more frequently than immediate adverse events and are the cause of significant morbidity. Recognition of the high frequency of delayed adverse events is important in the care of children receiving IVIG therapy.
记录儿童静脉注射免疫球蛋白（IVIG）后即刻和延迟不良事件（AE）的发生率。
前瞻性记录了58名接受IVIG治疗免疫缺陷（n = 33）或免疫调节（n = 25）的儿童的345次输注的即刻和延迟不良事件。每次输注时记录不良事件，并在4 - 7天后通过随访访谈记录。
在研究期间接受治疗的儿童中，10.3%发生了即刻不良事件，41.4%发生了延迟不良事件。3.5%的输注与即刻不良事件相关，20.9%与延迟不良事件相关。头痛是最常见的延迟不良事件，发生在24.1%的患者和12.8%的输注中。
IVIG输注的延迟不良事件在儿童中很常见。它们比即刻不良事件更频繁发生，并且是显著发病的原因。认识到延迟不良事件的高发生率对于接受IVIG治疗的儿童护理很重要。
